skip to Main Content
Biogen Update On Efficacy Of Nusinersen

Biogen update on efficacy of nusinersen

In infants with spinal muscular atrophy (SMA), treatment with Spinraza (nusinersen), the first FDA-approved drug for SMA, reduces the risk of death or permanent ventilation, according to new results from the Phase 3 ENDEAR study (NCT02193074).

Biogen presented the data at the British Paediatric Neurology Association (BPNA) annual conference Jan. 11-13 in Cambridge, England.

Read more at SMA News

Back To Top